Therapeutic utility of IFN administration has been primarily demonstrated in some leukaemia and from solid type of malignancies in renal cell carcinoma, Kaposi's sarcoma and malignant melanoma –(for review see Lens and Dawes, 2002). This evidence concerns the gene IFNA1 and melanoma.